Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 8,147 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: GI Disorders Clear all
Recruiting Phase 2 Interventional

Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease

NCT06638944
View directory record Official record
Conditions
Dysphagia, Stroke, Parkinson Disease
Interventions
In-person sEMG-biofeedback, Remote sEMG-biofeedback, Standard-of-care treatment
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
50 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Champaign, Illinois • West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 2:44 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD)

NCT00373334
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, GERD, Heartburn
Interventions
nizatidine (axid), placebo
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
30 Days to 1 Year
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
26
States / cities
Hot Springs, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2009 · Synced Oct 23, 2026, 2:44 AM EDT
Terminated Phase 1 Interventional

A Study of Niclosamide in Patients With Resectable Colon Cancer

NCT02687009
View directory record Official record
Conditions
Colon Cancer
Interventions
Niclosamide
Drug
Lead sponsor
Michael Morse, MD
Other
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 23, 2026, 2:44 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM

NCT01677299
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
EFB0027 (metformin delayed release), EFB0026 (metformin immediate-release)
Drug
Lead sponsor
Elcelyx Therapeutics, Inc.
Industry
Eligibility
19 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Oct 23, 2026, 2:44 AM EDT
Completed Not applicable Interventional Results available

Compare Propofol to Fentanyl and Midazolam for Colonoscopy

NCT01488045
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer, Colonic Diverticulosis
Interventions
Fentanyl, Propofol, Midazolam
Drug
Lead sponsor
Trinity Health Michigan
Other
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 23, 2026, 2:44 AM EDT
Terminated Phase 2 Interventional Results available

Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy

NCT01855607
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Neuropathy
Interventions
topical menthol, placebo lotion
Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 23, 2026, 2:44 AM EDT
Recruiting Phase 1 Interventional

Hypoxia Imaging for Esophageal Cancer to Guide Personalized Radiation Therapy

NCT04846309
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Radiation, FMISO PET CT
Radiation · Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 23, 2026, 2:44 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

NCT02586987
View directory record Official record
Conditions
Lung Cancer, Melanoma, Head and Neck Carcinoma, Gastroesophageal Cancer, Breast Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Biliary Tract Cancer
Interventions
Selumetinib, MEDI4736, Tremelimumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Chicago, Illinois • Boston, Massachusetts • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 23, 2026, 2:44 AM EDT
Completed Phase 2 Interventional Results available

Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer

NCT00114231
View directory record Official record
Conditions
Colorectal Cancer
Interventions
capecitabine, oxaliplatin, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
67
States / cities
Scottsdale, Arizona • Concord, California • Duarte, California + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 23, 2026, 2:44 AM EDT
Terminated Phase 3 Interventional

Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis

NCT01038739
View directory record Official record
Conditions
Diverticulitis
Interventions
Mesalazine, Placebo
Drug
Lead sponsor
Dr. Falk Pharma GmbH
Industry
Eligibility
30 Years to 80 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New Smyrna Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 23, 2026, 2:44 AM EDT
Completed Phase 1 Interventional

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03071757
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
ABBV-368, ABBV-181
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
La Jolla, California • Sacramento, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 23, 2026, 2:44 AM EDT
Completed Phase 1 Interventional

Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection

NCT03202992
View directory record Official record
Conditions
HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection, HIV Infection, Anal Cancer, Anus Neoplasms
Interventions
ABI-1968
Drug
Lead sponsor
Antiva Biosciences
Industry
Eligibility
27 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
San Francisco, California • Orlando, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Oct 23, 2026, 2:44 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT06979336
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
RO7837195, RO7837195 Matched Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Lancaster, California • San Diego, California • Colorado Springs, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 2:44 AM EDT
Recruiting Phase 2 Interventional

Study of DONQ52 in Active Celiac Disease

NCT07239336
View directory record Official record
Conditions
Celiac Disease
Interventions
Placebo DONQ52, Simulated Inadvertent Gluten Exposure (SIGE) capsule, DONQ52
Drug · Dietary Supplement
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years to 75 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
58
States / cities
Anniston, Alabama • Homewood, Alabama • Mobile, Alabama + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 23, 2026, 2:44 AM EDT
Recruiting Phase 1Phase 2 Interventional

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

NCT03965234
View directory record Official record
Conditions
Metastatic Bone Sarcoma, Metastatic Malignant Neoplasm in the Lung, Metastatic Soft Tissue Sarcoma, Metastatic Unresectable Sarcoma, Resectable Sarcoma, Colorectal Cancer
Interventions
Cisplatin, Isolated Chemotherapeutic Lung Perfusion, Metastasectomy
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 23, 2026, 2:44 AM EDT
Withdrawn Phase 2 Interventional

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

NCT06410534
View directory record Official record
Conditions
Colorectal Cancer, Gastroesophageal Cancer
Interventions
nivolumab, ipilimumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 23, 2026, 2:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines

NCT03897309
View directory record Official record
Conditions
Norovirus Infection
Interventions
VXA-G1.1-NN, VXA-G2.4-NS, Placebo Tablets
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 23, 2026, 2:44 AM EDT
Completed Not applicable Interventional Results available

Bone Health in Pediatric Crohn's Disease: A Low Magnitude Mechanical Stimulus Trial

NCT00364130
View directory record Official record
Conditions
Crohn Disease
Interventions
Low magnitude mechanical stimulus, Placebo (inactive) low magnitude mechanical stimulus
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 21 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 23, 2026, 2:44 AM EDT
Completed Phase 2 Interventional

Radiation Therapy and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Patients With Rectal Cancer

NCT00021398
View directory record Official record
Conditions
Colorectal Cancer
Interventions
fluorouracil, leucovorin calcium, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2018
U.S. locations
17
States / cities
Flemington, New Jersey • Lakewood, New Jersey • Mount Holly, New Jersey + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2020 · Synced Oct 23, 2026, 2:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma

NCT03961945
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Adenocarcinoma
Interventions
Sponge Capsule
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
1,526 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
8
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Austin, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 2:44 AM EDT
Not listed No phase listed Observational

Treatment of Perianal Disease Using Adipose-derived Stem Cells

NCT03913572
View directory record Official record
Conditions
Perianal Fistula, Crohn Disease
Interventions
Injection of adipose-derived stem cells into perianal fistula
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 23, 2026, 2:44 AM EDT
Recruiting Not applicable Interventional

Tailored Anti-Inflammatory American Diet for Patients With Crohn's Disease

NCT07671872
View directory record Official record
Conditions
Crohn's Disease, Active, Crohn's Disease (CD), Diet Interventions
Interventions
Catered Anti-Inflammatory Diet, Diet Guidance for Usual Diet
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
16 Years to 75 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 2:44 AM EDT
Completed Phase 3 Interventional Results available

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

NCT01607957
View directory record Official record
Conditions
Colorectal Cancer
Interventions
TAS-102, Placebo
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
23
States / cities
Glendale, Arizona • Fresno, California • Gilroy, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 23, 2026, 2:44 AM EDT
Active, not recruiting Not applicable Interventional Results available

Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial)

NCT01696981
View directory record Official record
Conditions
Colon Carcinoma, Rectal Carcinoma
Interventions
Screening Questionnaire Administration, Sigmoidoscopy
Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
55 Years to 74 Years
Enrollment
154,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 23, 2026, 2:44 AM EDT